GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2Results posted

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide sc Administered by 2 Different Products

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

103

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criteria

•BMI ≥25•Healthy volunteers

Primary endpoint

•Intensity of Injection Site Pain

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04007107

Org study IDINS-4582

Secondary ID2019-002284-10European Medicines Agency (EudraCT)

Secondary IDU1111-1233-9590World Health Organization (WHO)

Timeline

Milestones

Study start2019-06-27actual

Study first posted2019-07-05actual

Primary completion2019-07-28actual

Study completion2019-09-04actual

Last update posted2020-08-04actual

Results first posted2020-08-04actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

•Male or female subjects, aged 18 to 75 years (both inclusive) at the time of signing informed consent.

•BMI equal to or above 25.0 kg/m^2

•Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the Investigator.

Exclusion criteria

•Known or suspected hypersensitivity to the study product or related products.

•Previous participation in this study. Participation is defined as having received investigational product.

•Woman who is pregnant or breast-feeding or intends to become pregnant within 4 weeks after administration of the study drug, or is of childbearing potential and not using highly effective contraceptive methods with her fertile male sexual partner

•Participation in a drug study within 60 days prior to drug administration in the current study. Participation in more than 4 other drug studies in the 12 months prior to drug administration in the current study.

•Any disorder that in the Investigator's opinion might jeopardize subject's safety, evaluation of results, or compliance with the protocol.

•Glycosylated haemoglobin (HbA1c) equal to or above 6.5% at screening.

•Supine blood pressure at screening (after resting for at least 5 minutes) outside the range of 90 to 160 mmHg for systolic or 45 to 89 mmHg for diastolic.

•Supine pulse rate (as part of vital signs) (after resting for at least 5 minutes) outside the range of 40 to 100 beats per minute.

•Use of prescription medicinal products or non-prescription drugs or herbal products, except routine vitamins, topical medication, contraceptives, and occasional use of paracetamol (paracetamol not allowed within 24 hours prior to drug administration), within 14 days prior to drug administration.

•Diagnostic test results positive for human immunodeficiency virus (HIV)-1 or HIV-2 infection.

•Diagnostic test results positive for hepatitis B or hepatitis C infection.

•Mental incapacity, language barriers, or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or cooperation during the study as judged by the Investigator.

•Average intake of more than 21 units of alcohol per week for male subjects and more than 14 units per week for female subjects: 1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits.

•Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening and admission to the clinical research center.

•Use of tobacco and nicotine products, defined as any of the below:

•Smoking more than 1 cigarette or the equivalent per day on average

•Not able or willing to refrain from smoking and the use of nicotine substitute products during the in-house period

•Blood donation, plasma donation or blood draw (as declared by the subject or reported in the medical records):

•In excess of 400 mL within the past 90 days prior to the day of screening

•In excess of 50 mL within the past 30 days prior to the day of screening

•Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by the subject or reported in the medical records)

•Subjects with a history of malignant neoplasms within the past 5 years prior to screening.

•Presence or history of pancreatitis (acute or chronic; as declared by the subject or reported in the medical records).

•Subject is not able to understand and read English or Dutch, or subject is not able to understand and comply with the study requirements.

•Subject depends on the Sponsor, the Investigator, or the study center, or subject is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the study.

•Vulnerable subject (eg, person kept in detention) who may have an increased likelihood of being wronged or of incurring additional harm.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/registry result

Intensity of Injection Site Pain

Time frame:After 1 minute of each injection (Day 1)

descriptive

Posted result

Group	Value (mean), score on a scale	95% CI
DV3396	35.1	—
PDS290	4.4	—

Estimated treatment difference30.795% CI26.6 – 34.8p<0.0001ANOVA

Primary/protocol endpoint

Intensity of Injection Site Pain

Time frame:After 1 minute of each injection (Day 1)

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.
Diabetes, obesity & metabolism2022 Aug (month)PMID35434913doi:10.1111/dom.14718via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.